Answers are grounded in this paper and cite their sources.
In silico evaluation highlights bioactive compounds may improve obesity management by activating MC4R and GLP-1R.
Childhood obesity is strongly influenced by dysregulated appetite signalling, particularly within pathways involving melanocortin-4 receptor (MC4R) and glucagon-like peptide-1 receptor (GLP-1R). Phaseolus vulgaris has been reported to reduce body weight, yet its specific molecular interactions with appetite-regulating receptors remain unclear. This study aimed to evaluate the potential of P. vulgaris bioactive compounds as appetite-suppressing agents through MC4R and GLP-1R activation using an in silico approach. A total of 46 compounds were screened for physicochemical and ADMET properties using pkCSM, followed by molecular docking against MC4R and GLP-1R using PyRx. Interaction profiles were visualized with Discovery Studio, and docking validation was conducted using re-docking RMSD criteria. Twenty-six compounds met Lipinski's criteria and demonstrated acceptable pharmacokinetic profiles. Sterol derivatives, including stigmasterol, 24-α-methyllophenol, and obtusifoliol, showed the strongest binding affinities (AG -8.9 to -12.4 kcal/mol) and occupied key hydrophobic pockets similar to native agonists. Flavonoids and anthocyanins exhibited lower binding energies but formed extensive hydrogen-bond and aromatic interactions that may stabilize receptor-ligand complexes. These findings suggest that P. vulgaris seeds contain compounds with promising anorexigenic potential through MC4R and GLP-1R modulation. Further in vitro and in vivo studies are required to confirm their therapeutic relevance for obesity management.
No takes yet. Share an insight, caveat, or question.
Firzani et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: